Dawn Bell on Smart Risk

Dr. Dawn Bell is the Global Development Head, Strategic Partnerships at Novartis, a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. Novartis - one of the largest pharmaceutical companies in the world - is where Dawn leads business development and portfolio strategy for whitespace opportunities. Working in large pharma, mid-sized, and start-up companies, she has developed and launched 12 innovative medicines across 8 therapeutic areas. Dawn is energized by working with and advising founders and start-up CEOs through her role as a Mentor at Creative Destruction Lab, and Executive Council member in EIT Health’s Gold Track Program (Germany). She serves as a board advisor to two privately held, venture-backed drug discovery companies and board director for The Metabolomics Innovation Center, a nationally funded research facility based in Alberta, Canada.